US12551491 — Dosage regimens for benzgalantamine
Method of Use · Assigned to Alpha Cognition Inc · Expires 2045-07-23 · 19y remaining
What this patent protects
This patent protects a method of administering benzgalantamine gluconate to treat mild to moderate Alzheimer's disease dementia, using a specific dosage regimen.
USPTO Abstract
A method of effectively reducing the pharmaceutical load of galantamine relative to oral administration of galantamine or a method of effectively administering galantamine in a subject in need of galantamine therapy for the treatment of mild to moderate dementia of the Alzheimer's type, the methods including orally administering a dosage form of benzgalantamine gluconate according to the following dosage regime: administering a starting dosage of 5 mg benzgalantamine gluconate, twice daily, for a minimum of four weeks.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-713 |
— | benzgalantamine-gluconate |
U-713 |
— | benzgalantamine-gluconate |
U-713 |
— | benzgalantamine-gluconate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.